%A Zheng Lei, Song Zhengbo, Zhang Yiping %T Therapy for advanced nonsmall cell lung cancer using icotinib hydrochloride %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.01.016 %P 49-52 %V 41 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9279.shtml} %8 2014-01-08 %X Icotinib hydrochloride is a novel oral epidermal growth factor receptortyrosine kinase inhibitor, which shows obvious inhibitory effect on nonsmall cell lung cancer (NSCLC) in vitro and in vivo. The phase Ⅲ clinical study (ICOGEN) shows that icotinib has a good efficacy for advanced retreatment NSCLC, compared with gefitinib. It is indicated for the treatment of patients with locally advanced or metastatic NSCLC previously treated with one or two chemotherapy regimens. In the clinical treatment, icotinib shows the positive effects and mild adverse reactions, especially for the patients who have the EGFR mutation.